CliffBio
biologic

Humira

adalimumab

Loss of exclusivityNovember 2027projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameHumira
Active ingredientadalimumab
Strength40MG/0.4ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2015
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.